Zevra Therapeutics (ZVRA) Common Equity (2014 - 2026)
Zevra Therapeutics (ZVRA) posted Common Equity of $6000.0 for Q1 2026, little changed on a QoQ basis from $6000.0 in Q4 2025, and down 99.99% year-over-year from $41.0 million in Q1 2025.
Zevra Therapeutics (ZVRA) Common Equity (2014 - 2026) Analysis & Trends
Zevra Therapeutics' Common Equity history runs 13 years deep, the most recent figure standing at $6000.0 for Q1 2026.
- Quarterly Common Equity fell 99.99% year-over-year to $6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6000.0 (down 99.99% YoY) and the FY2025 annual result came in at $6000.0, down 99.98% from the prior year.
- Common Equity was $6000.0 for Q1 2026 at Zevra Therapeutics, roughly flat from $6000.0 in the prior quarter.
- Across five years, Common Equity topped out at $117.2 million in Q2 2025 and bottomed at -$16.7 million in Q3 2022.
- A 5-year average of $40.1 million and a median of $44.9 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity tumbled 112.7% — and 2023, when it soared 886.45%.
- Zevra Therapeutics' Common Equity stood at $75.1 million in 2022, then retreated by 17.65% to $61.9 million in 2023, then plunged by 35.88% to $39.7 million in 2024, then tumbled by 99.98% to $6000.0 in 2025, then changed by 0.0% to $6000.0 in 2026.
- Business Quant data shows ZVRA's Common Equity at $6000.0 in Q1 2026, $6000.0 in Q4 2025, and $6000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 117.23 Mn |
| Mar 31, 2025 | 41.02 Mn |
| Dec 31, 2024 | 39.67 Mn |
| Sep 30, 2024 | 69.77 Mn |
| Jun 30, 2024 | 32.48 Mn |
| Mar 31, 2024 | 48.82 Mn |
| Dec 31, 2023 | 61.86 Mn |
| Sep 30, 2023 | 61.52 Mn |
| Jun 30, 2023 | 58.87 Mn |
| Mar 31, 2023 | 59.27 Mn |
| Dec 31, 2022 | 75.12 Mn |
| Sep 30, 2022 | -16.74 Mn |
| Mar 31, 2022 | -7.54 Mn |
| Dec 31, 2021 | 101.66 Mn |
| Sep 30, 2021 | 131.74 Mn |
| Jun 30, 2021 | 130.66 Mn |
| Mar 31, 2021 | 84.25 Mn |